Last $43.69 USD
Change Today +0.02 / 0.05%
Volume 272.4K
RDY On Other Exchanges
Symbol
Exchange
New York
Natl India
Frankfurt
Mexico
As of 8:04 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Snapshot

Open
$43.78
Previous Close
$43.67
Day High
$44.05
Day Low
$43.32
52 Week High
02/27/14 - $47.93
52 Week Low
08/28/13 - $31.32
Market Cap
7.4B
Average Volume 10 Days
320.9K
EPS TTM
--
Shares Outstanding
170.3M
EX-Date
08/1/14
P/E TM
--
Dividend
$0.30
Dividend Yield
0.56%
Current Stock Chart for DOCTOR REDDY'S LAB-ADR (RDY)

Related News

No related news articles were found.

doctor reddy's lab-adr (RDY) Related Businessweek News

No Related Businessweek News Found

doctor reddy's lab-adr (RDY) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

doctor reddy's lab-adr (RDY) Top Compensated Officers

Co-Chairman, Managing Director, Chief Executi...
Total Annual Compensation: 6.3M
Chairman of the Board, Member of the Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy’s Laboratories Announces the Launch of Paricalcitol Capsules

Dr. Reddy’s Laboratories announced that it has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of ZEMPLAR® (Paricalcitol) Capsules in the US market on June 24, 2014, following the approval by the United States Food & Drug Administration (USFDA).

Dr. Reddy's Laboratories Announces the Launch of Duloxetine Delayed-Release Capsules USP

Dr. Reddy's Laboratories announced that it has launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of CYMBALTA in the US market on June 26, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration. The CYMBALTA brand and generic had U.S. sales of approximately $5.04 billion MAT for the most recent twelve months ending in April 2014, Dr. Reddy's Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts.

Dr. Reddy's Laboratories Ltd. Launches Paricalcitol Capsules

Dr. Reddy's Laboratories Ltd. announced that it has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of ZEMPLAR (Paricalcitol) Capsules in the US market on June 24, 2014, following the approval by USFDA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $43.69 USD +0.02

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Richter Gedeon Nyrt 4,220 -85.00
Cipla Ltd/India 436.05 INR -0.20
Endo International PLC $67.25 USD +0.07
Lupin Ltd 1,039 INR +1.05
Ranbaxy Laboratories Ltd 543.20 INR -0.10
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 21.2x
Price/Sales 3.5x
Price/Book 5.0x
Price/Cash Flow 21.2x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.